Compare NAVI & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAVI | EVO |
|---|---|---|
| Founded | 1973 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | NAVI | EVO |
|---|---|---|
| Price | $8.63 | $3.09 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $12.14 | $7.00 |
| AVG Volume (30 Days) | ★ 1.0M | 145.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $82.46 | N/A |
| Revenue Next Year | $12.45 | $7.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.36 | $2.84 |
| 52 Week High | $16.07 | $4.80 |
| Indicator | NAVI | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 22.71 | 33.68 |
| Support Level | N/A | $2.87 |
| Resistance Level | $13.34 | $3.78 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 16.00 | 14.29 |
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.